Microbion Corp is a clinical-stage pharmaceutical company based in Bozeman, MT, dedicated to developing a new class of compounds for the treatment of challenging infections, including chronic and antibiotic-resistant infections. Their lead therapeutic candidate, Pravibismane, is a groundbreaking anti-infective drug that effectively prevents and eradicates biofilms, which contribute to chronic infections and antibiotic resistance.
With a focus on site-specific delivery, Microbion's innovative approach avoids systemic administration of their compounds, resulting in higher therapeutic concentration at the site of infection, improved safety profile, and reduced risk of antibiotic resistance. They have ongoing Phase 2 clinical programs for diabetic foot ulcer infection and orthopedic implant infection, as well as preclinical programs for the treatment of serious respiratory infections.
Generated from the website